Allogeneic Stem Cell Transplantation: Does the Conditioning Regimen Intensity Still Matter?
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Hematology".
Deadline for manuscript submissions: 31 January 2025 | Viewed by 254
Special Issue Editor
Special Issue Information
Dear Colleagues,
With the discovery of the alloimmune anti-tumour effect of allogeneic hematopoietic cell transplantation, reduced-intensity pre-transplant regimens emerged in order to decrease toxicity associated with myeloablation. In most transplanted diseases, a certain amount of myeloablation is required to achieve a low relapse risk, whereas in other contexts, the toxicity of myeloablation outweighs the anti-tumour effect of conditioning, leading us to favour reduced-intensity regimens. Efforts are ongoing to find the “sweet spot” of lowest toxicity and mortality together with the lowest risk of relapse. However, few randomised trials comparing conditioning regimens have been conducted, and transplantation teams often use regimens they are familiar with. Recent developments include the reduction in total body irradiation doses, and the increasing use of new molecules, such as treosulfan and thiotepa. The development of new regimens also challenges the very definitions of regimen intensity.
In this Special Issue of Current Oncology, we welcome the submission of original research reports as well as review articles focusing on conditioning regimens prior to allogeneic hematopoietic cell transplantation.
Dr. Imran Ahmad
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- conditioning
- preparative
- regimen
- allogeneic
- hematopoietic
- transplantation
- myeloablative
- nonmyeloablative
- reduced
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
